Medi Assist Healthcare Services Ltd Q1 FY27 Earnings Analysis

- Core group business organic growth currently tracking at 8%-10% (same-store growth). - Historical post-COVID same-store growth peaked at 20%-25%, now moderating. - Growth rates influenced by IT-ITES slowdown; other industries like oil & gas, chemical, manufacturing showing promising life growth. - Technology SaaS platform revenue grew 91.9% YoY, contributing 2.5% of total revenue, expected to scale further. - International business pipeline built; markets like Southeast Asia targeted for expansion. - Expected technology business to achieve 1.5x to 2x higher margin than traditional TPA business. - Paramount acquisition integration expected to complete in 1-2 quarters, improving margins. - Government business growing strongly (42.6% YoY), with increasing public health engagement. - Long-term vision aligned with government initiatives aiming for insurance coverage growth toward 2047. - EBITDA margin expansion seen; Q4 margin at 19.9%.

- Medi Assist expects continued growth driven by core TPA business, technology SaaS platform, international business, and new acquisitions (e.g., Paramount). - Technology business currently contributes 2.5% of revenue but is growing rapidly (~91.9% YoY) with potential for higher-margin outcome-based pricing in future. - International business pipeline is strong, especially in Southeast Asia; limited exposure to Middle East conflict. - EBITDA margin improved steadily, reaching 19.9% in Q4 FY26; operating EBITDA grew 13.3% YoY. - Adjusted PAT stood at INR 68.8 crores for FY26 after exceptional items. - Organic group business expected to grow at 8-10% on blended same-store growth despite IT-ITES sector slowdown, supported by diversified industry clientele. - Margin expansion and revenue growth anticipated over next 1-2 quarters from Paramount integration. - Long-term growth supported by increasing health insurance penetration and government digital initiatives.

- The transcript does not explicitly mention any specific current or planned capex or capital investments. - The company is focused on technology development, particularly AI and SaaS platforms, which are implied investments in tech capabilities. - There is significant emphasis on integration of acquisitions (e.g., Paramount) over 4-5 quarters, which may involve some strategic investments related to operational scaling. - Expansion into international markets like Southeast Asia and Thailand suggests potential strategic investments in those regions. - Continued partnerships and integrations with government digital health platforms (e.g., National Health Claims Exchange) imply ongoing investment in technology infrastructure. - No specific figures or detailed plans related to capex or strategic investments are disclosed on the provided pages.

- As of the latest update on May 11, 2026, Medi Assist Healthcare Services Limited reported that the group became debt-free in January 2026. - There is no mention of any current or planned fundraising through debt or equity in the provided document. - The company focuses on growing organically and via acquisitions like Paramount but does not indicate plans for raising capital through debt or equity. - Free cash flow position is strong at INR 260.5 crores, and net worth is INR 852.4 crores, supporting financial stability without immediate need for external fundraising. - No disclosures or guidance related to future fundraising activities were provided during the conference or in the financial highlights.

- As per the transcript, Medi Assist Healthcare Services Limited disclosed a contract liability of INR 280.2 crores as of March 31, 2026. - This contract liability represents revenue that is committed but has not yet been recognized in the Profit & Loss statement. - The contract liability can be understood as the current order book or pending revenue from signed contracts that will be recognized in future periods. - The company indicated that a significant portion of revenue is recognized on a 12-month service basis, contributing to this contract liability. - There is no explicit disclosure of new pending orders beyond this contract liability figure in the transcript.